Strategic Partnerships

We are very excited about our current collaborations and are focused on researching and developing innovative therapies for these collaboration targets. We look forward to exploring additional collaboration opportunities should one arise.

Sanofi

In January 2020, Nurix entered into a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases.

Gilead Sciences, Inc.

In June 2019, Nurix entered into a global strategic collaboration with Gilead to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.